Τίτλος:
Metabolic phenotype of male obesity-related secondary hypogonadism
pre-replacement and post-replacement therapy with intra-muscular
testosterone undecanoate therapy
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
To explore the metabolic phenotype of obesity-related secondary
hypogonadism (SH) in men pre-replacement and post-replacement therapy
with long-acting intramuscular (IM) testosterone undecanoate (TU).
A prospective observational pilot study on metabolic effects of TU IM in
male obesity-related SH (hypogonadal [HG] group, n = 13), including
baseline comparisons with controls (eugonadal [EG] group, n = 15).
Half the subjects (n = 7 in each group) had type 2 diabetes mellitus
(T2D). Baseline metabolic assessment on Human Metabolism Research Unit:
fasting blood samples; BodPod (body composition), and; whole-body
indirect calorimetry. The HG group was treated with TU IM therapy for
6-29 months (mean 14.8-months [SD 8.7]), and assessment at the Human
Metabolism Research Unit repeated. T-test comparisons were performed
between baseline and follow-up data (HG group), and between baseline
data (HG and EG groups). Data reported as mean (SD).
Overall, TU IM therapy resulted in a statistically significant
improvement in HbA1C (9 mmol/mol, P = 0.03), with 52% improvement in
HOMA%B. Improvement in glycaemic control was driven by the HG subgroup
with T2D, with 18 mmol/mol [P = 0.02] improvement in HbA1C. Following
TU IM therapy, there was a statistically significant reduction in fat
mass (3.5 Kg, P = 0.03) and increase in lean body mass (2.9 kg, P =
0.03). Lipid profiles and energy expenditure were unchanged following TU
IM therapy. Comparisons between baseline data for HG and EG groups were
equivalent apart from differences in testosterone, SHBG and basal
metabolic rate (BMR).
In men with obesity-related SH (including a subgroup with T2D), TU IM
therapy improved glycaemic control, beta cell function, and body
composition.
Συγγραφείς:
Dimitriadis, Georgios K.
Randeva, Harpal S.
Aftab, Saboor and
Ali, Asad
Hattersley, John G.
Pandey, Sarojini and
Grammatopoulos, Dimitris K.
Valsamakis, Georgios
Mastorakos,
Georgios
Jones, T. Hugh
Barber, Thomas M.
Περιοδικό:
Endocrine Development
Λέξεις-κλειδιά:
Male obesity-associated secondary hypogonadism; Testosterone
replacement; Obesity; Secondary Hypogonadism; Testosterone; Type 2
Diabetes Mellitus
DOI:
10.1007/s12020-017-1516-x
